Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine

  title={Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine},
  author={Philipp Zimmer and Andreas Mierau and Wilhelm Bloch and Heiko Klaus Str{\"u}der and Thorben H{\"u}lsd{\"u}nker and Alexander Schenk and Leonie Fiebig and Freek T Baumann and Moritz Hahn and Nina Reinart and Michael Hallek and Thomas Elter},
  journal={Leukemia \& Lymphoma},
  pages={347 - 352}
Abstract To assess the effects of chemoimmunotherapy on post-chemotherapy cognitive impairments (PCCI) in patients with B-cell non-Hodgkin lymphoma (NHL), we used objective and subjective measures of cognitive functions in combination with serum parameters and neuroelectric recordings. Self-perceived status of cognition, fatigue and emotional functioning were reduced in patients (n = 30) compared to healthy controls (n = 10). Cognitive performance was impaired in patients with NHL compared to… 
Early manifestation of mild cognitive impairment in B-cell non-Hodgkin’s lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy
Patients receiving R-CHOP regimen were found to have more increased IL-6 and IL-1β with more cognitive decline and thyroid abnormality as comparison to CHOP receiving patients.
[Chemotherapy-related Cognitive Impairment in Patients with Hodgkin Lymphoma - Pathophysiology and Risk Factors].
The most frequently observed changes in cognitive function in patients suffering from CRCI are summarized and the possible pathophysiological mechanisms behind these changes and the risk factors that can increase the likelihood of cognitive functional impairment after chemotherapy of malignant tumors are described.
Neurocognitive function of lymphoma patients after treatment with chemotherapy
Protection of the brain by ‘cognitive or brain reserve’ as a possible explanation for the effects of chemotherapy on the cognitive function of lymphoma patients is hypothesized.
Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment
Higher-risk patients experienced impairments in executive function and memory suggesting that disease biology contributes to CRCI independent of treatment, according to Sociodemographic-adjusted linear regression models.
Electrophysiological biomarkers of chemotherapy-related cognitive impairment in hematological malignancy patients
Outcome measures provide initial support for contributions from both tumor biology and chemotherapy toxicity to functional changes in attentional control network activity and both cancer groups showed evidence for reduced information processing capacity while completing a simulation of naturalistic driving behavior.
Cognitive impairment and chemotherapy: a brief overview.
Influence of polychemotherapy on cognitive functions in patients with lymphoproliferative diseases: literature review and personal clinical observations
Cognitive defects negatively influence patients’ quality of life, significantly reduce their physical and mental working ability, everyday activity, make execution of professional duties difficult, besides they can complicate nursing.
Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology
This review has examined some commonly used drugs for the treatment of hematological malignancies which are known to have a deleterious action on cognitive functions and the interactions between genetic risk, amyloid accumulation, intrinsic brain networks, and chemotherapy.
What is known and unknown about chemotherapy‐related cognitive impairment in patients with haematological malignancies and areas of needed research
It appears that a subset of chemotherapy‐treated haematological malignancy survivors experience CRCI, and future research should focus on expanding the literature reviewed here with larger studies appropriately powered to assess cognition via objective and subjective measures in a longitudinal fashion to tease apart the impact of disease and the various forms of cancer treatment.


A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients
The results suggest that having a breast cancer diagnosis may be associated with cognitive impairment, and chemotherapy-related impairments appear to be more acute than chronic side effects of therapy.
Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.
High-dose chemotherapy appears to impair cognitive functioning more than standard- dose chemotherapy, and central nervous system toxicity may be a dose-limiting factor in high-dose cancer treatment regimens.
Chemotherapy-related cognitive impairment.
  • J. Myers
  • Psychology, Biology
    Clinical journal of oncology nursing
  • 2009
Oncology nurses should be aware of available resources, such as relevant Web sites, support groups, neuropsychologists, and cognitive retraining programs, and provide support for patients concerned about or experiencing CRCI.
Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily
QoL is only temporarily affected during (R)-CHOP-14-based chemotherapy, and the treatment regimen is therefore feasible, in conclusion.
Neurophysiological Evaluation of Late Effects of Adjuvant High-dose Chemotherapy on Cognitive Function
There is neurophysiological support for cognitive dysfunction as a late complication of high-dose systemic chemotherapy in breast cancer, according to a randomized study in high-risk breast cancer patients.
Electrophysiological Correlates of Information Processing in Breast-Cancer Patients Treated With Adjuvant Chemotherapy
The data provide further evidence for long-term neurocognitive problems in breast-cancer patients treated with adjuvant (CMF) chemotherapy and offer new information regarding abnormalities in brain functioning in these patients.
Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?
This study confirms high rates of behavioral symptoms in breast cancer survivors, particularly those treated with chemotherapy, and indicates a role for TNF-α signaling as a contributor to postchemotherapy fatigue.
Accumulating evidence for the effect of chemotherapy on cognition.
  • G. Rodin, T. Ahles
  • Psychology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
Age and education were not shown to moderate the effects of chemotherapy-induced cognitive change in the present meta-analysis, and those older patients with low levels of pretreatment cognitive reserve who were exposed to chemotherapy were most vulnerable to post-treatment cognitive decline.